TW201619605A - 用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法 - Google Patents
用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法 Download PDFInfo
- Publication number
- TW201619605A TW201619605A TW104135033A TW104135033A TW201619605A TW 201619605 A TW201619605 A TW 201619605A TW 104135033 A TW104135033 A TW 104135033A TW 104135033 A TW104135033 A TW 104135033A TW 201619605 A TW201619605 A TW 201619605A
- Authority
- TW
- Taiwan
- Prior art keywords
- stratum corneum
- protease inhibitor
- serine protease
- region
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 95
- 238000011156 evaluation Methods 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title abstract description 4
- 230000003796 beauty Effects 0.000 title abstract description 3
- 230000006813 corneocyte desquamation Effects 0.000 title abstract 6
- 230000000694 effects Effects 0.000 claims abstract description 77
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 36
- 239000003112 inhibitor Substances 0.000 claims abstract description 35
- 230000001737 promoting effect Effects 0.000 claims abstract description 30
- 238000012216 screening Methods 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 210000000434 stratum corneum Anatomy 0.000 claims description 175
- 239000003001 serine protease inhibitor Substances 0.000 claims description 124
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 121
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 121
- 210000003491 skin Anatomy 0.000 claims description 63
- 238000004299 exfoliation Methods 0.000 claims description 62
- 230000005764 inhibitory process Effects 0.000 claims description 48
- 102000004142 Trypsin Human genes 0.000 claims description 44
- 108090000631 Trypsin Proteins 0.000 claims description 43
- 239000012588 trypsin Substances 0.000 claims description 43
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 31
- 230000003584 silencer Effects 0.000 claims description 24
- 210000004748 cultured cell Anatomy 0.000 claims description 20
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 16
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 206010021198 ichthyosis Diseases 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- 108010076876 Keratins Proteins 0.000 claims description 9
- 102000011782 Keratins Human genes 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 102000012479 Serine Proteases Human genes 0.000 claims description 8
- 108010022999 Serine Proteases Proteins 0.000 claims description 8
- 102000001400 Tryptase Human genes 0.000 claims description 8
- 108060005989 Tryptase Proteins 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 208000011219 Netherton syndrome Diseases 0.000 claims description 6
- 210000005175 epidermal keratinocyte Anatomy 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 230000001743 silencing effect Effects 0.000 claims description 5
- 230000009759 skin aging Effects 0.000 claims description 5
- 210000003802 sputum Anatomy 0.000 claims description 5
- 208000024794 sputum Diseases 0.000 claims description 5
- 230000036561 sun exposure Effects 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 4
- 230000037336 dry skin Effects 0.000 claims description 4
- 230000001530 keratinolytic effect Effects 0.000 claims description 4
- 229940124091 Keratolytic Drugs 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims description 2
- 239000003410 keratolytic agent Substances 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 abstract description 12
- 239000002753 trypsin inhibitor Substances 0.000 abstract description 11
- 101000847952 Homo sapiens Trypsin-3 Proteins 0.000 abstract description 8
- 102100034396 Trypsin-3 Human genes 0.000 abstract description 8
- 239000004365 Protease Substances 0.000 abstract description 6
- 229940122618 Trypsin inhibitor Drugs 0.000 abstract description 6
- 101710162629 Trypsin inhibitor Proteins 0.000 abstract description 5
- 101710159985 Serpin B12 Proteins 0.000 abstract description 4
- 102100032321 Serpin B12 Human genes 0.000 abstract description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 23
- 210000002510 keratinocyte Anatomy 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 239000010410 layer Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 230000002441 reversible effect Effects 0.000 description 13
- 210000002706 plastid Anatomy 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100034868 Kallikrein-5 Human genes 0.000 description 10
- 108010027252 Trypsinogen Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 101001091379 Homo sapiens Kallikrein-5 Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 7
- 102000018690 Trypsinogen Human genes 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034870 Kallikrein-8 Human genes 0.000 description 6
- 230000004888 barrier function Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 235000019833 protease Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108091005508 Acid proteases Proteins 0.000 description 5
- 101001091371 Homo sapiens Kallikrein-8 Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 239000012096 transfection reagent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100034867 Kallikrein-7 Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000003780 keratinization Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000968 medical method and process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150044802 B12 gene Proteins 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 3
- 101000848014 Homo sapiens Trypsin-2 Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 102000005806 Serine Peptidase Inhibitor Kazal-Type 5 Human genes 0.000 description 3
- 108010005020 Serine Peptidase Inhibitor Kazal-Type 5 Proteins 0.000 description 3
- 102100034392 Trypsin-2 Human genes 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- LQSLBVXESNRILG-VDGAXYAQSA-N Boc-Gln-Ala-Arg-7-amino-4-methylcoumarin Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)OC(C)(C)C)C)=CC=C21 LQSLBVXESNRILG-VDGAXYAQSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000005708 Desmoglein 1 Human genes 0.000 description 2
- 108010045579 Desmoglein 1 Proteins 0.000 description 2
- 108010022355 Fibroins Proteins 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 102100038297 Kallikrein-1 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100032491 Serine protease 1 Human genes 0.000 description 2
- 101710151387 Serine protease 1 Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910000420 cerium oxide Inorganic materials 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 101001090103 Arabidopsis thaliana Kunitz trypsin inhibitor 4 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002160 Celluloid Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000655897 Homo sapiens Serine protease 1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 101710176219 Kallikrein-1 Proteins 0.000 description 1
- 101710176223 Kallikrein-5 Proteins 0.000 description 1
- 101710176222 Kallikrein-7 Proteins 0.000 description 1
- 101710176225 Kallikrein-8 Proteins 0.000 description 1
- 108010093811 Kazal Pancreatic Trypsin Inhibitor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- DMGNFLJBACZMRM-UHFFFAOYSA-N O[P] Chemical compound O[P] DMGNFLJBACZMRM-UHFFFAOYSA-N 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 101150118944 PRSS1 gene Proteins 0.000 description 1
- 101150052381 PRSS2 gene Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000010847 SEQUEST Methods 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- -1 pH 6.3 Chemical compound 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
- G01N2333/8121—Serpins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Birds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014217823 | 2014-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201619605A true TW201619605A (zh) | 2016-06-01 |
Family
ID=55761021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104135033A TW201619605A (zh) | 2014-10-24 | 2015-10-23 | 用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6738280B2 (ja) |
| TW (1) | TW201619605A (ja) |
| WO (1) | WO2016063991A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050850A (zh) * | 2017-06-16 | 2020-04-21 | 阿兹特拉公司 | 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI861113B (zh) * | 2019-05-23 | 2024-11-11 | 日商寶麗化成工業股份有限公司 | 影響角質層細胞間的黏著蛋白之增減的成分之篩選方法 |
| WO2022025109A1 (ja) * | 2020-07-29 | 2022-02-03 | 味の素株式会社 | シワ改善用組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| FR2772612B1 (fr) * | 1997-12-19 | 2003-01-10 | Oreal | Utilisation de l'acide cinnamique ou de ses derives dans une composition cosmetique raffermissante |
| JP5241058B2 (ja) * | 2003-11-27 | 2013-07-17 | 株式会社 資生堂 | 不全角化抑制剤及び毛穴縮小剤 |
| JP4373318B2 (ja) * | 2003-11-27 | 2009-11-25 | 株式会社資生堂 | 不全角化抑制剤及び皮膚外用組成物 |
| JP5014592B2 (ja) * | 2005-05-25 | 2012-08-29 | 株式会社 資生堂 | 不全角化抑制剤、毛穴縮小剤，肌荒れ防止・改善剤 |
| CN101227885A (zh) * | 2005-07-26 | 2008-07-23 | 株式会社资生堂 | 皱纹防止·改善剂 |
| JP5063947B2 (ja) * | 2006-07-18 | 2012-10-31 | 株式会社ナリス化粧品 | アクロレイン付加体形成阻害剤、及びそれを含有する皮膚抗老化外用剤および抗老化飲食品 |
| JP4676448B2 (ja) * | 2007-01-22 | 2011-04-27 | 株式会社マルハニチロ水産 | タンパク質分解酵素阻害因子発現増強剤及びそれを含む皮膚の保水率改善剤 |
| EP2123253B1 (en) * | 2007-03-16 | 2017-06-28 | Shiseido Company, Ltd. | Wrinkling-preventing and -alleviating agent |
| CN101977626A (zh) * | 2008-01-21 | 2011-02-16 | 德莫迪斯公司 | 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 |
| JP2012006902A (ja) * | 2010-05-25 | 2012-01-12 | Shiseido Co Ltd | 肌改善のための外用剤セット及びこれを使用する美容方法 |
| JP2012051873A (ja) * | 2010-08-05 | 2012-03-15 | Shiseido Co Ltd | 皮膚化粧料 |
| TW201309334A (zh) * | 2011-02-25 | 2013-03-01 | 資生堂股份有限公司 | 角質層剝離促進劑 |
| FR2987057B1 (fr) * | 2012-02-17 | 2015-09-04 | Oreal | Genes bio-marqueurs pour selectionner et evaluer l'efficacite de protection d'un produit solaire face a des uva longs |
-
2015
- 2015-10-23 JP JP2016555420A patent/JP6738280B2/ja active Active
- 2015-10-23 TW TW104135033A patent/TW201619605A/zh unknown
- 2015-10-23 WO PCT/JP2015/080035 patent/WO2016063991A1/ja not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050850A (zh) * | 2017-06-16 | 2020-04-21 | 阿兹特拉公司 | 用于用表达lekti的重组微生物治疗内瑟顿综合征的组合物和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2016063991A1 (ja) | 2017-08-31 |
| JP6738280B2 (ja) | 2020-08-12 |
| WO2016063991A1 (ja) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Identification of a protective microglial state mediated by miR-155 and interferon-γ signaling in a mouse model of Alzheimer’s disease | |
| Blackburn et al. | Quantitative proteomic analysis of human airway cilia identifies previously uncharacterized proteins of high abundance | |
| O'Regan et al. | Filaggrin in atopic dermatitis | |
| Sugimoto et al. | Hepatic stellate cells control liver zonation, size and functions via R-spondin 3 | |
| Dokoshi et al. | Skin inflammation activates intestinal stromal fibroblasts and promotes colitis | |
| JP2018503632A (ja) | 非分解性異常タンパク質の蓄積に関連した障害またはがんの治療のためのプロテアソーム阻害剤 | |
| Uzunhan et al. | Mesenchymal stem cells protect from hypoxia-induced alveolar epithelial-mesenchymal transition | |
| KR101286833B1 (ko) | 편평상피세포암 관련 항원을 지표로 하는 피부 성상의 평가방법 | |
| JP2024056774A (ja) | アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物 | |
| US20110305783A1 (en) | Method and pharmaceutical composition for treating psoriasis, squamous cell carcinoma and/or parakeratosis by inhibiting expression of squamous cell carcinoma-related antigen | |
| Huang et al. | Gasdermin A is required for epidermal cornification during skin barrier regeneration and in an atopic dermatitis-like model | |
| TW201619605A (zh) | 用以改善起因於角質層剝離之抑制或促進之肌膚狀態的美容方法及評價方法 | |
| Niehues et al. | CYSRT1: An antimicrobial epidermal protein that can interact with late cornified envelope proteins | |
| WO2004064857A1 (ja) | ガレクチン９含有医薬 | |
| WO2006095086A2 (fr) | Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. | |
| Yu et al. | Phosphorylation of FOXN3 by NEK6 promotes pulmonary fibrosis through Smad signaling | |
| Howell et al. | Not that rigid midgets and not so flexible giants: on the abundance and roles of intrinsic disorder in short and long proteins | |
| Wagner et al. | Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models | |
| Guignard et al. | Chymotrypsin activity signals to intestinal epithelium by protease‐activated receptor‐dependent mechanisms | |
| ES2895628T3 (es) | Inhibidores de GSK3B en el tratamiento de trastornos de hipopigmentación | |
| Naydenov et al. | The septin cytoskeleton is a novel regulator of intestinal epithelial barrier integrity and mucosal inflammation | |
| JP6602317B2 (ja) | ｉＲＨＯＭポリペプチドの活性を変化させる化合物を同定する方法及びその使用 | |
| JP2006213621A (ja) | Ａｄｏｐｌｉｎタンパク質、およびその利用 | |
| Li et al. | A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses | |
| CN113786488A (zh) | 蛋白酶体19s调节性颗粒亚基psmd11作为靶点用于预防或治疗癌症 |